Go to BioCentury homepage
Print this Print this
Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Daiichi Sankyo Co. Ltd.

Print preview Print preview

(Tokyo:4568; Osaka:4568)

Collapse Summary

General Information
 Location Tokyo, Japan
 Region
 Country Japan
 Business Category Pharmaceuticals
 Year Founded 1899
 Website www.daiichisankyo.co.jp
 Development Status Market (drug) (11/29/2006)

Archive Items are loading
Collapse Summary

Pipeline Information
Disease CategoryResearchPhase IPhase I/IIPhase IIPhase II/IIIPhase IIIRegistrationApprovedMarketed
Cancer

-

3

-

19

-

3

-

2

-

Cardiovascular

-

1

-

1

-

2

2

1

2

Dental

-

-

-

-

-

-

-

-

1

Dermatology

-

-

-

1

-

-

-

-

-

Diagnostic

-

-

-

-

-

-

-

-

1

Endocrine

-

-

-

1

-

2

-

-

1

Genitourinary

-

-

-

-

-

-

-

1

-

Hematology

-

-

-

1

-

-

-

-

2

Infectious

-

-

-

-

-

1

-

-

-

Metabolic

-

-

-

-

-

-

-

-

2

Musculoskeletal

-

-

-

-

-

-

1

-

-

Neurology

-

1

-

1

-

-

-

-

-

Total

-

5

-

24

-

8

3

4

9

Pipeline Details - Originated and out-licensed products (23 records)

Product Names

Disease Category

Standard Indication

Partners

Milestones

Latest Stage of Development

Benicar (Brand), Olmesatan medoxomil (Brand), medoxomil (Chemical), CS-866 (Compound #), olmesartan (Generic), Benicar (Other)

Cardiovascular

Hypertension

 

 

Marketed

Benicar (Brand), Olmesatan medoxomil (Brand), medoxomil (Chemical), CS-866 (Compound #), olmesartan (Generic), Benicar (Other)

Endocrine

Diabetes

 

 

Phase III
More

Pipeline Details - In-licensed products (31 records)

Product NamesDisease CategoryStandard IndicationIn-licensed fromMilestonesLatest Stage of DevelopmentRights

AMG 162 (Compound #), denosumab (Generic), Prolia (Other)

Cancer

Bone metastases

Amgen Inc.

 

Phase III

Full

AMG 162 (Compound #), denosumab (Generic), Prolia (Other)

Musculoskeletal

Osteoporosis

Amgen Inc.

PDUFA date (10/19/2009)

Registration

Full
More